Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash & Equivalents (2019 - 2025)

Cyclerion Therapeutics has reported Cash & Equivalents over the past 7 years, most recently at $3.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents changed 0.25% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, changed 0.25%, while the annual FY2025 figure was $3.2 million, 0.25% changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $3.2 million at Cyclerion Therapeutics, down from $4.6 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $70.4 million in Q2 2021 and troughed at $2.9 million in Q3 2024.
  • A 5-year average of $19.7 million and a median of $7.4 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 82.57% in 2023 and later soared 59.05% in 2025.
  • Year by year, Cash & Equivalents stood at $54.0 million in 2021, then plummeted by 75.2% to $13.4 million in 2022, then plummeted by 43.42% to $7.6 million in 2023, then crashed by 57.31% to $3.2 million in 2024, then grew by 0.25% to $3.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for CYCN at $3.2 million in Q4 2025, $4.6 million in Q3 2025, and $3.0 million in Q2 2025.